Definitive Contract 75N95024C00020
Award Date
7/10/24
Potential Completion Date
7/9/29
Potential Value
$7.8M
Federal Agency
National Institute on Drug Abuse
Awardee
Virginia Commonwealth University
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Richmond, VA 23298, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $5,833,141.44 cost-reimbursable contract awarded by the National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services, to Virginia Commonwealth University (VCU) for medication discovery research using rat models of drug relapse. The contract has a period of performance from July 10, 2019 to July 9, 2024, with the initial award covering the first year. This contract was awarded under a competitive solicitation that was open to small businesses only, but no...
This is a cost-reimbursement contract awarded by the National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services, to Virginia Commonwealth University (VCU) for $11,354,157.46. The contract is for preclinical medication discovery and abuse liability testing services in support of NIDA's mission. The contract has a period of performance from February 22, 2017 to February 21, 2018, with a potential completion date of February 16, 2025. This award is not...
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $382,010.00 Firm Fixed Price Delivery Order contract to Vitae Enim Vitae Scientific, Inc. (VEV Scientific) on September 27, 2024. The contract is for dosage form reprocessing and stability studies of the FX-5A injection drug product under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Chemistry, Manufacturing and Controls (CMC) and related services to support drug product development. The contract...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $1,436,776 firm fixed price delivery order to Altasciences Clinical Kansas Inc. to conduct a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent from September 3, 2024 to March 2, 2026. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for pharmacokinetic and pharmacodynamic...
This federal contract award, with a ceiling value of $1,927,163.66, was issued by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services. The contract was awarded to SRI International, a non-profit research and development organization, and is part of NIDA's Pharmacology and Toxicology for Neurotherapeutics Program (PTNP). The contract, which is a Delivery Order under the PTNP Indefinite Delivery Vehicle (IDV), is for IND-enabling studies....
This federal contract award, valued at $7,096,467, was issued by the National Institute on Drug Abuse (NIDA) to the University of North Texas Health Science Center at Fort Worth (UNTHSC). The contract is to use rodent behavioral models to identify potential pharmacotherapies for substance use disorders. UNTHSC, a U.S. state government entity and educational institution, has extensive experience providing medical, scientific, and forensic services to federal agencies. The center has existing...
This federal contract award is a delivery order under a larger contract vehicle, with Research Triangle Institute (RTI) International as the prime contractor. The contract is with the National Institute on Drug Abuse (NIDA), a civilian agency within the Department of Health and Human Services (HHS). The award, valued at $376,358.00, is for the synthesis and distribution of drugs of abuse and related compounds over a one-year period from June 16, 2024 to June 15, 2025, with a total period of...
This federal contract award is for the evaluation of a potential respiratory stimulant on behalf of the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). The award, with a ceiling value of $140,848.00, was issued to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The scope of work includes nonclinical animal studies to assess potential treatments for drug-induced respiratory depression and...
This is a $4,026,071.62 cost-plus-fixed-fee contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the National Institutes of Health, to SD Solutions LLC, an 8(a) small disadvantaged business based in Rockville, Maryland. The contract is for the NIDA Clinical Trials Research Coordination Center, which will provide logistical and operational support services for NIDA's National Drug Abuse Treatment Clinical Trials Network. This includes coordinating meetings,...
<p>The National Institute on Drug Abuse (NIDA), a civilian agency, awarded a $24,999.10 firm fixed-price purchase order to Vizioli Omics to complete research and analysis leading to the submission of manuscripts for publication. The contract, which does not have a set-aside designation, has a period of performance through June 24, 2025. This award appears to be for a standalone project and is not associated with a larger contract vehicle.</p>